{
    "clinical_study": {
        "@rank": "48818", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.   Determine the safety and efficacy of tobramycin in patients with cystic\n      fibrosis who are chronically colonized with Pseudomonas aeruginosa.\n\n      II.  Determine whether this treatment produces tobramycin-resistant bacteria at a frequency\n      different from the placebo group and whether the emergence of resistance is associated with\n      a lack of clinical response."
        }, 
        "brief_title": "Phase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic Fibrosis", 
        "completion_date": "May 1998", 
        "condition": [
            "Cystic Fibrosis", 
            "Bacterial Infection"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bacterial Infections", 
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study.\n\n      Patients receive tobramycin or placebo by inhalation twice daily for 28 days followed by 28\n      days of rest.  This treatment is repeated twice, for a total of 3 courses of therapy.\n\n      Patients are followed every 2 weeks for the first 8 weeks, then every 4 weeks, and then at 4\n      weeks after the last treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Documented cystic fibrosis with Pseudomonas aeruginosa present in a sputum or throat\n        culture within 6 months prior to screening\n\n        Sweat chloride at least 60 mEq/L\n\n        --Prior/Concurrent Therapy--\n\n        At least 14 days since prior intravenous or aerosolized tobramycin or other\n        antipseudomonal antibiotic\n\n        At least 4 weeks since prior administration of any investigational drug\n\n        No concurrent antibiotics by aerosol\n\n        --Patient Characteristics--\n\n        Renal:\n\n          -  Creatinine less than 2 mg/dL\n\n          -  BUN less than 40 mg/dL\n\n          -  No proteinuria of 2+ or greater\n\n        Pulmonary:\n\n          -  FEV1 at least 75% and at least 25% of predicted\n\n          -  Room air oximetry at least 88% saturation\n\n          -  Able to perform pulmonary function tests\n\n          -  No hemoptysis of 60 mL or greater within 30 days prior to study\n\n          -  No abnormal chest X-ray\n\n        Other:\n\n          -  Not pregnant\n\n          -  Fertile females must use effective contraception\n\n          -  No history of positive culture with Burkholderia cepacia\n\n          -  No history of glucose-6-phosphate dehydrogenase deficiency\n\n          -  No known local or systemic hypersensitivity to aminoglycosides, albuterol, or other\n             beta-2 agonists"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": "200", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004829", 
            "org_study_id": "199/13390", 
            "secondary_id": [
                "PATH-PG-TNDS-002/003", 
                "PATH-FDR001235"
            ]
        }, 
        "intervention": {
            "intervention_name": "tobramycin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Tobramycin"
        }, 
        "keyword": [
            "bacterial infection", 
            "cardiovascular and respiratory diseases", 
            "cystic fibrosis", 
            "genetic diseases and dysmorphic syndromes", 
            "immunologic disorders and infectious disorders", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Pathogenesis", 
            "last_name": "Alan Bruce Montgomery", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "reference": {
            "PMID": "9878641", 
            "citation": "Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999 Jan 7;340(1):23-30."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004829"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "June 1995", 
        "study_design": "Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1998"
    }, 
    "geocoordinates": {}
}